The suitability of BV2 cells as alternative model system for primary microglia cultures or for animal experiments examining brain inflammation (original) (raw)
Authors
- Anja Henn Doerenkamp-Zbinden Chair for alternative in vitro methods to replace animal experiments, University of Konstanz, Konstanz, Germany
- Søren Lund Novo Nordisk A/S, Bagsværd, Denmark
- Maj Hedtjärn Santaris Pharma A/S, Hørsholm, Denmark
- André Schrattenholz ProteoSys AG, Mainz, Germany
- Peter Pörzgen Hawaii Pacific University, Kaneohe, USA
- Marcel Leist Doerenkamp-Zbinden Chair for alternative in vitro methods to replace animal experiments, University of Konstanz, Konstanz, Germany
DOI:
https://doi.org/10.14573/altex.2009.2.83
Keywords:
microglia, inflammation, BV-2, transcriptome, replacement
Abstract
The role of microglia in neurodegeneration, toxicology and immunity is an expanding area of biomedical research requiring large numbers of animals. Use of a microglia-like cell line would accelerate many research programmes and reduce the necessity of continuous cell preparations and animal experimentation, provided that the cell line reproduces the in vivo situation or primary microglia (PM) with high fidelity. The immortalised murine microglial cell line BV-2 has been used frequently as a substitute for PM, but recently doubts were raised as to their suitability. Here, we re-evaluated strengths and potential shortcomings of BV-2 cells. Their response to lipopolysaccharide was compared with the response of microglia in vitro and in vivo. Transcriptome (480 genes) and proteome analyses after stimulation with lipopolysaccharide indicated a reaction pattern of BV-2 with many similarities to that of PM, although the average upregulation of genes was less pronounced. The cells showed a normal regulation of NO production and a functional response to IFN-γ, important parameters for appropriate interaction with T cells and neurons. BV-2 were also able to stimulate other glial cells. They triggered the translocation of NF-κB, and a subsequent production of IL-6 in astrocytes. Thus, BV-2 cells appear to be a valid substitute for PM in many experimental settings, including complex cell-cell interaction studies.
License
Articles are distributed under the terms of the Creative Commons Attribution 4.0 International license (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium, provided the original work is appropriately cited (CC-BY). Copyright on any article in ALTEX is retained by the author(s).
How to Cite
“The suitability of BV2 cells as alternative model system for primary microglia cultures or for animal experiments examining brain inflammation” (2009) ALTEX - Alternatives to Animal Experimentation, 26(2), pp. 83–94. doi:10.14573/altex.2009.2.83.
Most read articles by the same author(s)
- Lucy Meigs, Lena Smirnova, Costanza Rovida, Marcel Leist, Thomas Hartung, Animal testing and its alternatives – the most important omics is economics, ALTEX - Alternatives to Animal Experimentation: Vol. 35 No. 3 (2018)
- David Pamies, Marcel Leist, Sandra Coecke, Gerard Bowe, David G. Allen, Gerhard Gstraunthaler, Anna Bal-Price, Francesca Pistollato, Rob B. M. de Vries, Helena T. Hogberg, Thomas Hartung, Glyn Stacey, Guidance document on Good Cell and Tissue Culture Practice 2.0 (GCCP 2.0), ALTEX - Alternatives to Animal Experimentation: Vol. 39 No. 1 (2022)
- Marcel Leist, Silvia Tangianu, Femke Affourtit, Hedwig Braakhuis, John Colbourne, Eike Cöllen, Nadine Dreser, Sylvia E. Escher, Iain Gardner, Stefan Hahn, Barry Hardy, Matthias Herzler, Barira Islam, Hennicke Kamp, Viktoria Magel, Philip Marx-Stoelting, Martijn J. Moné, Patrik Lundquist, Ilse Ottenbros, Gladys Ouedraogo, Giorgia Pallocca, Bob van de Water, Mathieu Vinken, Andrew White, Manuel Pastor, Mirjam Luijten, An Alternative Safety Profiling Algorithm (ASPA) to transform next generation risk assessment into a structured and transparent process, ALTEX - Alternatives to Animal Experimentation: Vol. 43 No. 1 (2026)
- Ronit Mohapatra, Marcel Leist, Sonja von Aulock, Thomas Hartung, Guidance for Good In Vitro Reporting Standards (GIVReSt) – A draft for stakeholder discussion and background documentation, ALTEX - Alternatives to Animal Experimentation: Vol. 42 No. 3 (2025)
- Thomas Hartung, Lena Smirnova, Stefan Platz, Ivano Amelio, Marcel Leist, The need for epigenotoxicity testing, ALTEX - Alternatives to Animal Experimentation: Vol. 42 No. 4 (2025)
- Uwe Marx, Takafumi Akabane, Tommy B. Andersson, Elizabeth Baker, Mario Beilmann, Sonja Beken, Susanne Brendler-Schwaab, Murat Cirit, Rhiannon David, Eva-Maria Dehne, Isabell Durieux, Lorna Ewart, Suzanne C. Fitzpatrick, Olivier Frey, Florian Fuchs, Linda G. Griffith, Geraldine A. Hamilton, Thomas Hartung, Julia Hoeng, Helena Hogberg, David J. Hughes, Donald E. Ingber, Anita Iskandar, Toshiyuki Kanamori, Hajime Kojima, Jochen Kuehnl, Marcel Leist, Bo Li, Peter Loskill, Donna L. Mendrick, Thomas Neumann, Giorgia Pallocca, Ivan Rusyn, Lena Smirnova, Thomas Steger-Hartmann, Danilo A. Tagle, Alexander Tonevitsky, Sergej Tsyb, Martin Trapecar, Bob van de Water, Janny van den Eijnden-van Raaij, Paul Vulto, Kengo Watanabe, Armin Wolf, Xiaobing Zhou, Adrian Roth, Biology-inspired microphysiological systems to advance patient benefit and animal welfare in drug development, ALTEX - Alternatives to Animal Experimentation: Vol. 37 No. 3 (2020)
- Ivana Celardo, Michael Aschner, Randolph S. Ashton, Kelly E. Carstens, Andrea Cediel-Ulloa, Eike Cöllen, Kevin M. Crofton, Susan J. Debad, Nadine Dreser, Suzanne Fitzpatrick, Ellen Fritsche, Sebastian Gutsfeld, Barry Hardy, Thomas Hartung, Ellen Hessel, Harm Heusinkveld, Helena T. Hogberg, Jui-Hua Hsieh, Yasunari Kanda, Gavin T. Knight, Thomas Knudsen, Katharina Koch, Eliska Kuchovska, Iris Mangas, M. Sue Marty, Stephanie Melching-Kollmuss, Iris Müller, Patrick Müller, Oddvar Myhre, Martin Paparella, Emily Pitzer, Anna Bal-Price, Magdalini Sachana, Kevin Schlüppmann, Timothy J. Shafer, Jasmin Schäfer, Lena Smirnova, Tamara Tal, Yaroslav Tanaskov, Silvia Tangianu, Giuseppe Testa, Anna-Katharina Ückert, Maurice Whelan, Marcel Leist, Developmental neurotoxicity (DNT): A call for implementation of new approach methodologies for regulatory purposes: Summary of the 5th International Conference on DNT Testing, ALTEX - Alternatives to Animal Experimentation: Vol. 42 No. 2 (2025)
- Uwe Marx, Sonja Beken, Zaozao Chen, Eva-Maria Dehne, Ann Doherty, Lorna Ewart, Suzanne C. Fitzpatrick, Linda G. Griffith, Zhongze Gu, Thomas Hartung, James Hickman, Donald E. Ingber, Seiichi Ishida, Jayoung Jeong, Marcel Leist, Lisa Levin, Donna L. Mendrick, Giorgia Pallocca, Stefan Platz, Marian Raschke, Lena Smirnova, Danilo A. Tagle, Martin Trapecar, Bas W. M. van Balkom, Janny van den Eijnden-van Raaij, Andries van der Meer, Adrian Roth, Biology-inspired dynamic microphysiological system approaches to revolutionize basic research, healthcare and animal welfare , ALTEX - Alternatives to Animal Experimentation: Vol. 42 No. 2 (2025)
- Thomas Hartung, Nicholas M. P. King, Nicole Kleinstreuer, Marcel Leist, Danilo A. Tagle, Leveraging biomarkers and translational medicine for preclinical safety - Lessons for advancing the validation of alternatives to animal testing, ALTEX - Alternatives to Animal Experimentation: Vol. 41 No. 4 (2024)
- Alice Krebs, Tanja Waldmann, Martin F. Wilks, Barbara M. A. van Vugt-Lussenburg, Bart van der Burg, Andrea Terron, Thomas Steger-Hartmann, Joelle Ruegg, Costanza Rovida, Emma Pedersen, Giorgia Pallocca, Mirjam Luijten, Sofia B. Leite, Stefan Kustermann, Hennicke Kamp, Julia Hoeng, Philip Hewitt, Matthias Herzler, Jan G. Hengstler, Tuula Heinonen, Thomas Hartung, Barry Hardy, Florian Gantner, Ellen Fritsche, Kristina Fant, Janine Ezendam, Thomas Exner, Torsten Dunkern, Daniel R. Dietrich, Sandra Coecke, Francois Busquet, Albert Braeuning, Olesja Bondarenko, Susanne H. Bennekou, Mario Beilmann, Marcel Leist, Template for the description of cell-based toxicological test methods to allow evaluation and regulatory use of the data, ALTEX - Alternatives to Animal Experimentation: Vol. 36 No. 4 (2019)